Supernus Depreciation And Amortization vs Extraordinary Items Analysis

SUPN Stock

USD 29.10 0.06 0.21%

Supernus Pharmaceuticals financial indicator trend analysis is much more than just breaking down Supernus Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Supernus Pharmaceuticals is a good investment. Please check the relationship between Supernus Pharmaceuticals Depreciation And Amortization and its Extraordinary Items accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

Depreciation And Amortization vs Extraordinary Items

Depreciation And Amortization vs Extraordinary Items Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Supernus Pharmaceuticals Depreciation And Amortization account and Extraordinary Items. At this time, the significance of the direction appears to have strong relationship.

The correlation between Supernus Pharmaceuticals' Depreciation And Amortization and Extraordinary Items is 0.71. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Extraordinary Items in the same time period over historical financial statements of Supernus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Supernus Pharmaceuticals' Depreciation And Amortization and Extraordinary Items is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of Supernus Pharmaceuticals are associated (or correlated) with its Extraordinary Items. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Extraordinary Items has no effect on the direction of Depreciation And Amortization i.e., Supernus Pharmaceuticals' Depreciation And Amortization and Extraordinary Items go up and down completely randomly.

Correlation Coefficient

0.71

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Extraordinary Items

Most indicators from Supernus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Supernus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.At this time, Supernus Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 17th of May 2024, Issuance Of Capital Stock is likely to grow to about 8.4 M, while Selling General Administrative is likely to drop about 73.8 M.

	2021	2022	2023	2024 (projected)
Interest Expense	23.4M	7.1M	2.4M	2.3M
Depreciation And Amortization	34.0M	82.6M	84.9M	89.1M

Interest Expense Depreciation And Amortization

Supernus Pharmaceuticals fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock
Common Stock Shares Outstanding		0.64	0.48	0.36	0.61	0.63	0.42	0.42	0.47	0.35	0.46	0.61	-0.14	0.64	0.7	0.93	0.6	0.45	0.58	0.64	0.91	0.63	0.53	0.69	0.45	0.94
Total Assets	0.64		0.74	0.63	0.81	0.98	0.77	0.7	0.95	0.63	0.64	0.99	-0.38	0.9	0.98	0.62	0.81	0.76	0.93	0.89	0.84	0.94	0.91	0.94	0.88	0.61
Short Long Term Debt Total	0.48	0.74		0.08	0.7	0.6	0.35	0.94	0.57	0.76	0.76	0.69	-0.56	0.92	0.66	0.4	0.75	0.83	0.54	0.75	0.65	0.91	0.68	0.87	0.5	0.43
Other Current Liab	0.36	0.63	0.08		0.45	0.74	0.62	0.13	0.74	-0.01	0.05	0.65	0.05	0.38	0.69	0.38	0.5	0.2	0.73	0.39	0.46	0.38	0.44	0.45	0.66	0.34
Total Current Liabilities	0.61	0.81	0.7	0.45		0.77	0.41	0.79	0.78	0.72	0.31	0.78	-0.42	0.82	0.82	0.54	0.94	0.41	0.83	0.73	0.7	0.83	0.65	0.87	0.78	0.54
Total Stockholder Equity	0.63	0.98	0.6	0.74	0.77		0.84	0.57	0.97	0.51	0.53	0.99	-0.27	0.82	0.98	0.63	0.77	0.66	0.94	0.83	0.81	0.85	0.9	0.87	0.89	0.61
Property Plant And Equipment Net	0.42	0.77	0.35	0.62	0.41	0.84		0.27	0.82	0.18	0.48	0.8	0.08	0.58	0.75	0.46	0.47	0.57	0.68	0.6	0.61	0.59	0.89	0.61	0.64	0.43
Net Debt	0.42	0.7	0.94	0.13	0.79	0.57	0.27		0.58	0.74	0.51	0.66	-0.61	0.85	0.62	0.3	0.83	0.64	0.58	0.66	0.55	0.85	0.61	0.82	0.53	0.32
Retained Earnings	0.47	0.95	0.57	0.74	0.78	0.97	0.82	0.58		0.52	0.44	0.96	-0.28	0.78	0.94	0.46	0.75	0.6	0.94	0.79	0.69	0.82	0.88	0.83	0.92	0.43
Accounts Payable	0.35	0.63	0.76	-0.01	0.72	0.51	0.18	0.74	0.52		0.54	0.62	-0.71	0.66	0.57	0.3	0.57	0.59	0.62	0.78	0.5	0.78	0.57	0.7	0.69	0.33
Cash	0.46	0.64	0.76	0.05	0.31	0.53	0.48	0.51	0.44	0.54		0.6	-0.27	0.75	0.58	0.47	0.36	0.91	0.35	0.68	0.64	0.74	0.64	0.7	0.35	0.51
Non Current Assets Total	0.61	0.99	0.69	0.65	0.78	0.99	0.8	0.66	0.96	0.62	0.6		-0.38	0.86	0.98	0.6	0.77	0.75	0.94	0.89	0.82	0.91	0.92	0.91	0.9	0.59
Non Currrent Assets Other	-0.14	-0.38	-0.56	0.05	-0.42	-0.27	0.08	-0.61	-0.28	-0.71	-0.27	-0.38		-0.38	-0.31	-0.12	-0.34	-0.46	-0.4	-0.6	-0.29	-0.52	-0.29	-0.42	-0.45	-0.14
Cash And Short Term Investments	0.64	0.9	0.92	0.38	0.82	0.82	0.58	0.85	0.78	0.66	0.75	0.86	-0.38		0.87	0.61	0.88	0.79	0.72	0.82	0.83	0.96	0.8	0.98	0.66	0.62
Net Receivables	0.7	0.98	0.66	0.69	0.82	0.98	0.75	0.62	0.94	0.57	0.58	0.98	-0.31	0.87		0.66	0.79	0.68	0.93	0.86	0.85	0.89	0.85	0.92	0.88	0.66
Common Stock Total Equity	0.93	0.62	0.4	0.38	0.54	0.63	0.46	0.3	0.46	0.3	0.47	0.6	-0.12	0.61	0.66		0.57	0.44	0.54	0.66	0.93	0.58	0.53	0.66	0.43	0.99
Short Term Investments	0.6	0.81	0.75	0.5	0.94	0.77	0.47	0.83	0.75	0.57	0.36	0.77	-0.34	0.88	0.79	0.57		0.46	0.76	0.67	0.73	0.83	0.66	0.89	0.67	0.56
Non Current Liabilities Total	0.45	0.76	0.83	0.2	0.41	0.66	0.57	0.64	0.6	0.59	0.91	0.75	-0.46	0.79	0.68	0.44	0.46		0.53	0.82	0.69	0.85	0.76	0.78	0.52	0.45
Inventory	0.58	0.93	0.54	0.73	0.83	0.94	0.68	0.58	0.94	0.62	0.35	0.94	-0.4	0.72	0.93	0.54	0.76	0.53		0.82	0.73	0.81	0.8	0.81	0.97	0.53
Other Current Assets	0.64	0.89	0.75	0.39	0.73	0.83	0.6	0.66	0.79	0.78	0.68	0.89	-0.6	0.82	0.86	0.66	0.67	0.82	0.82		0.85	0.93	0.83	0.89	0.83	0.64
Other Stockholder Equity	0.91	0.84	0.65	0.46	0.7	0.81	0.61	0.55	0.69	0.5	0.64	0.82	-0.29	0.83	0.85	0.93	0.73	0.69	0.73	0.85		0.83	0.75	0.87	0.64	0.92
Total Liab	0.63	0.94	0.91	0.38	0.83	0.85	0.59	0.85	0.82	0.78	0.74	0.91	-0.52	0.96	0.89	0.58	0.83	0.85	0.81	0.93	0.83		0.84	0.98	0.77	0.59
Property Plant And Equipment Gross	0.53	0.91	0.68	0.44	0.65	0.9	0.89	0.61	0.88	0.57	0.64	0.92	-0.29	0.8	0.85	0.53	0.66	0.76	0.8	0.83	0.75	0.84		0.82	0.77	0.53
Total Current Assets	0.69	0.94	0.87	0.45	0.87	0.87	0.61	0.82	0.83	0.7	0.7	0.91	-0.42	0.98	0.92	0.66	0.89	0.78	0.81	0.89	0.87	0.98	0.82		0.75	0.66
Intangible Assets	0.45	0.88	0.5	0.66	0.78	0.89	0.64	0.53	0.92	0.69	0.35	0.9	-0.45	0.66	0.88	0.43	0.67	0.52	0.97	0.83	0.64	0.77	0.77	0.75		0.42
Common Stock	0.94	0.61	0.43	0.34	0.54	0.61	0.43	0.32	0.43	0.33	0.51	0.59	-0.14	0.62	0.66	0.99	0.56	0.45	0.53	0.64	0.92	0.59	0.53	0.66	0.42

Click cells to compare fundamentals

Supernus Pharmaceuticals Account Relationship Matchups

Supernus Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	53.8M	53.7M	54.4M	61.7M	55.5M	42.6M
Total Assets	1.2B	1.5B	1.7B	1.7B	1.4B	1.5B
Short Long Term Debt Total	375.6M	390.3M	420.6M	438.0M	41.5M	39.5M
Other Current Liab	3.2M	40.0M	65.0M	139.8M	279.9M	293.9M
Total Current Liabilities	160.6M	245.1M	315.4M	688.0M	290.2M	154.7M
Total Stockholder Equity	595.4M	744.9M	815.9M	886.2M	921.5M	967.6M
Property Plant And Equipment Net	38.3M	37.8M	17.0M	15.2M	42.5M	44.7M
Net Debt	194.2M	101.7M	217.1M	344.8M	(33.5M)	(31.9M)
Retained Earnings	199.5M	326.5M	379.9M	481.2M	482.6M	506.7M
Accounts Payable	10.1M	78.9M	117.7M	96.3M	2.0M	1.9M
Cash	181.4M	288.6M	203.4M	93.1M	75.1M	116.1M
Non Current Assets Total	687.6M	873.7M	1.1B	968.4M	915.9M	961.7M
Non Currrent Assets Other	615K	8.0M	(36.1M)	(10.0M)	8.5M	8.9M
Cash And Short Term Investments	347.1M	422.5M	339.7M	461.3M	254.9M	201.2M
Net Receivables	87.3M	140.9M	148.9M	165.5M	144.2M	151.4M
Common Stock Total Equity	51K	52K	53K	54K	62.1K	40.8K
Short Term Investments	165.7M	133.9M	136.2M	368.2M	179.8M	98.1M
Liabilities And Stockholders Equity	1.2B	1.5B	1.7B	1.7B	1.4B	1.5B
Non Current Liabilities Total	404.3M	514.1M	557.9M	128.3M	197.3M	179.2M
Inventory	26.6M	48.3M	86.0M	91.5M	77.4M	81.3M
Other Current Assets	11.6M	18.7M	27.0M	15.8M	16.7M	8.5M
Other Stockholder Equity	388.4M	409.3M	434.3M	408.1M	439.5M	279.8M
Total Liab	564.9M	759.2M	873.3M	816.3M	487.5M	333.9M
Property Plant And Equipment Gross	38.3M	37.8M	33.4M	28.2M	28.9M	30.4M
Total Current Assets	472.6M	630.4M	601.6M	734.2M	493.1M	305.3M
Accumulated Other Comprehensive Income	7.4M	9.0M	1.5M	(3.2M)	(593K)	(563.4K)
Intangible Assets	24.8M	442.3M	784.7M	702.5M	599.9M	629.9M
Common Stock	51K	52K	53K	54K	55K	42.0K
Other Liab	28.7M	123.8M	137.4M	92.3M	106.2M	111.5M
Current Deferred Revenue	144.4M	122.4M	126.2M	49.8M	1.0	0.95
Other Assets	32.7M	259.7M	13.9M	10.9M	12.5M	11.9M
Long Term Debt	329.5M	345.2M	361.8M	379.3M	436.1M	457.9M
Short Term Debt	2.8M	3.8M	6.5M	402.0M	8.3M	7.9M
Property Plant Equipment	17.1M	37.8M	52.3M	44.1M	50.7M	53.2M
Net Tangible Assets	570.6M	302.6M	(86.4M)	66.7M	76.7M	72.9M
Good Will	24.8M	77.9M	117.5M	117.0M	134.6M	141.3M
Retained Earnings Total Equity	199.5M	326.5M	379.9M	481.2M	553.4M	581.1M
Capital Surpluse	388.4M	409.3M	434.3M	408.1M	469.3M	352.1M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:

How To Invest In Supernus

Details

Is Supernus Stock a good investment?

Details

What is Supernus Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Supernus Stock analysis

When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Stocks Directory Find actively traded stocks across global markets
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Equity Valuation Check real value of public entities based on technical and fundamental data

Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.99)

Earnings Share

(0.29)

Revenue Per Share

10.933

Quarterly Revenue Growth

(0.07)

Return On Assets

0.0023

The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Supernus Depreciation And Amortization vs Extraordinary Items Analysis

Depreciation And Amortization vs Extraordinary Items

Depreciation And Amortization vs Extraordinary Items Correlation Analysis

Correlation Coefficient

Depreciation And Amortization

Extraordinary Items

Supernus Pharmaceuticals fundamental ratios Correlations

Supernus Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Supernus Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Supernus Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Stockholder Equity
Common Stock	+ 0.99	Common Stock Total Equity
Total Stockholder Equity	+ 0.98	Total Assets
Net Receivables	+ 0.98	Total Assets
Net Receivables	+ 0.98	Total Stockholder Equity

Non Currrent Assets Other	- 0.71	Accounts Payable
Non Currrent Assets Other	- 0.61	Net Debt
Other Current Assets	- 0.6	Non Currrent Assets Other
Non Currrent Assets Other	- 0.56	Short Long Term Debt Total
Total Liab	- 0.52	Non Currrent Assets Other
Non Current Liabilities Total	- 0.46	Non Currrent Assets Other